ASXL1 and myelodysplastic syndrome: Considering the adverse prognostic parameters identified in our study, a risk model including elderly age, and co‐mutations of RUNX1 and ASXL1‐G646W could be reasonably presumed in patients with MDS, and large‐sample multicenter studies are needed.